Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 1:59 pm Sale |
2024-12-31 | 13G | Inozyme Pharma, Inc. INZY |
Samlyn Capital, LLC | 0 0.000% |
-3,372,558 (Position Closed) |
Filing History |
| 2024-12-09 4:14 pm Purchase |
2024-12-02 | 13G | Inozyme Pharma, Inc. INZY |
Affinity Healthcare Fund, LP | 3,972,318 6.180% |
3,972,318 (New Position) |
Filing History |
| 2024-11-14 12:19 pm Purchase |
2024-09-30 | 13G | Inozyme Pharma, Inc. INZY |
Eventide Asset Management, LLC | 4,134,436 6.440% |
954,599 (+30.02%) |
Filing History |
| 2024-11-08 2:17 pm Unchanged |
2024-09-30 | 13G | Inozyme Pharma, Inc. INZY |
BLACKROCK INC BLK |
3,491,236 5.600% |
0 (Unchanged) |
Filing History |
| 2024-10-24 2:02 pm Purchase |
2024-09-30 | 13G | Inozyme Pharma, Inc. INZY |
BLACKROCK INC BLK |
3,491,236 5.600% |
3,491,236 (New Position) |
Filing History |
| 2024-02-20 7:11 pm Purchase |
2023-07-28 | 13D | Inozyme Pharma, Inc. INZY |
Sofinnova Venture Partners X L.P. | 4,280,308 6.900% |
2,252,000 (+111.03%) |
Filing History |
| 2024-02-14 8:34 pm Sale |
2023-12-31 | 13G | Inozyme Pharma, Inc. INZY |
Venrock Healthcare Capital Partners II, L.P. | 0 0.000% |
-3,867,749 (Position Closed) |
Filing History |
| 2024-02-14 6:08 pm Sale |
2023-12-31 | 13G | Inozyme Pharma, Inc. INZY |
New Enterprise Associates 15 L.P. | 0 0.000% |
-2,437,689 (Position Closed) |
Filing History |
| 2024-02-14 4:21 pm Sale |
2023-12-31 | 13G | Inozyme Pharma, Inc. INZY |
Baker Bros. Advisors LP | 0 0.000% |
-2,168,000 (Position Closed) |
Filing History |
| 2024-02-14 2:10 pm Purchase |
2023-12-31 | 13G | Inozyme Pharma, Inc. INZY |
Rock Springs Capital Management LP | 3,681,174 5.960% |
595,147 (+19.29%) |
Filing History |
| 2024-02-14 1:40 pm Purchase |
2023-12-31 | 13G | Inozyme Pharma, Inc. INZY |
Samlyn Capital, LLC | 3,372,558 5.500% |
3,372,558 (New Position) |
Filing History |
| 2024-02-14 11:54 am Purchase |
2023-12-31 | 13G | Inozyme Pharma, Inc. INZY |
Eventide Asset Management, LLC | 3,179,837 5.150% |
3,179,837 (New Position) |
Filing History |
| 2024-02-14 08:48 am Sale |
2023-12-31 | 13G | Inozyme Pharma, Inc. INZY |
Deep Track Capital, LP | 0 0.000% |
-3,250,000 (Position Closed) |
Filing History |
| 2024-02-12 9:06 pm Unchanged |
2024-02-12 | 13D | Inozyme Pharma, Inc. INZY |
Pivotal bioVenture Partners Fund I L.P. | 4,494,851 7.200% |
0 (Unchanged) |
Filing History |
| 2024-02-07 07:46 am Purchase |
2023-12-31 | 13G | Inozyme Pharma, Inc. INZY |
ADAGE CAPITAL PARTNERS GP LLC | 5,537,500 8.970% |
2,437,362 (+78.62%) |
Filing History |
| 2024-02-05 09:12 am Sale |
2023-12-31 | 13G | Inozyme Pharma, Inc. INZY |
Sphera Funds Management Ltd. | 1,562,907 2.530% |
-533,351 (-25.44%) |
Filing History |
| 2024-01-16 4:12 pm Sale |
2023-12-31 | 13G | Inozyme Pharma, Inc. INZY |
MILLENNIUM MANAGEMENT LLC | 911,465 1.500% |
-1,381,362 (-60.25%) |
Filing History |
| 2023-08-11 4:08 pm Purchase |
2023-08-01 | 13D | Inozyme Pharma, Inc. INZY |
Longitude Capital Partners III LLC | 5,841,045 9.900% |
1,666,666 (+39.93%) |
Filing History |
| 2023-08-07 9:58 pm Purchase |
2023-08-01 | 13D | Inozyme Pharma, Inc. INZY |
Pivotal bioVenture Partners Fund I L.P. | 4,494,851 9.500% |
833,333 (+22.76%) |
Filing History |
| 2023-05-31 4:17 pm Purchase |
2023-05-22 | 13G | Inozyme Pharma, Inc. INZY |
MILLENNIUM MANAGEMENT LLC | 2,292,827 5.200% |
2,292,827 (New Position) |
Filing History |